ECSP099071A - Agonistas de ep2 - Google Patents

Agonistas de ep2

Info

Publication number
ECSP099071A
ECSP099071A EC2009009071A ECSP099071A ECSP099071A EC SP099071 A ECSP099071 A EC SP099071A EC 2009009071 A EC2009009071 A EC 2009009071A EC SP099071 A ECSP099071 A EC SP099071A EC SP099071 A ECSP099071 A EC SP099071A
Authority
EC
Ecuador
Prior art keywords
agonists
compounds
methods
preparation
provides
Prior art date
Application number
EC2009009071A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP099071A publication Critical patent/ECSP099071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

La invención proporciona agonistas de EP2, procedimientos para su preparación, composiciones farmacéuticas que contienen estos compuestos y procedimientos de uso de estos compuestos y composiciones para reducir la presión intraocular y tratar así el glaucoma.
EC2009009071A 2006-07-28 2009-01-14 Agonistas de ep2 ECSP099071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
ECSP099071A true ECSP099071A (es) 2009-02-27

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009071A ECSP099071A (es) 2006-07-28 2009-01-14 Agonistas de ep2

Country Status (25)

Country Link
US (2) US7622475B2 (es)
EP (1) EP2059507B1 (es)
JP (1) JP4583500B2 (es)
KR (1) KR101088942B1 (es)
AP (1) AP2009004754A0 (es)
AR (1) AR062122A1 (es)
AU (1) AU2007280130B2 (es)
BR (1) BRPI0714683A2 (es)
CA (1) CA2659184C (es)
CL (1) CL2007002207A1 (es)
CR (1) CR10554A (es)
EA (1) EA200970067A1 (es)
EC (1) ECSP099071A (es)
GT (1) GT200700064A (es)
IL (1) IL196355A0 (es)
MA (1) MA30604B1 (es)
MX (1) MX2009001062A (es)
NO (1) NO20090738L (es)
NZ (1) NZ573964A (es)
PE (1) PE20080408A1 (es)
RS (1) RS20090002A (es)
TN (1) TN2009000028A1 (es)
TW (1) TWI372757B (es)
UY (1) UY30511A1 (es)
WO (1) WO2008015517A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
CN102498101A (zh) * 2009-09-11 2012-06-13 宇部兴产株式会社 苯胺化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
KR20120101722A (ko) 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
EP2755944B1 (en) 2011-09-16 2017-06-14 Sanofi Biarylderivatives,their preparation and their therapeutic application
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
WO2013164326A1 (en) 2012-05-03 2013-11-07 Takeda Gmbh Novel ep2 receptor agonists
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
BR112015024743A2 (pt) * 2013-03-28 2017-07-18 Ube Industries composto de biarila substituída
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
AU2002348948A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Pharmaceutical compositions and methods for administering EP2 receptors selective agonists
PY0300568A (es) * 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
RS20090002A (sr) 2010-06-30
CA2659184C (en) 2012-02-21
NO20090738L (no) 2009-04-27
CR10554A (es) 2009-02-10
IL196355A0 (en) 2009-09-22
US20080045545A1 (en) 2008-02-21
HK1133876A1 (en) 2010-04-09
CL2007002207A1 (es) 2008-02-01
MX2009001062A (es) 2009-02-06
AU2007280130B2 (en) 2011-09-22
JP2009544751A (ja) 2009-12-17
AU2007280130A1 (en) 2008-02-07
JP4583500B2 (ja) 2010-11-17
AP2009004754A0 (en) 2009-02-28
WO2008015517A3 (en) 2008-06-12
EA200970067A1 (ru) 2009-08-28
EP2059507A2 (en) 2009-05-20
US7622475B2 (en) 2009-11-24
NZ573964A (en) 2010-11-26
PE20080408A1 (es) 2008-04-28
TWI372757B (en) 2012-09-21
EP2059507B1 (en) 2013-03-20
US20100105905A1 (en) 2010-04-29
MA30604B1 (fr) 2009-07-01
WO2008015517A2 (en) 2008-02-07
BRPI0714683A2 (pt) 2013-03-26
KR101088942B1 (ko) 2011-12-01
GT200700064A (es) 2009-06-18
TN2009000028A1 (fr) 2010-08-19
AR062122A1 (es) 2008-10-15
KR20090023507A (ko) 2009-03-04
CA2659184A1 (en) 2008-02-07
UY30511A1 (es) 2008-02-29
TW200817360A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
UY30511A1 (es) Agonistas de ep2
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA200970156A1 (ru) Пиридизиноновые производные
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
ECSP10010693A (es) Compuestos pirazólicos 436
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.